UCLA and UC Davis are embarking on a groundbreaking research initiative that could reshape the landscape of breast cancer screening in the United States. Funded by a substantial $16 million grant from the Patient-Centered Outcomes Research Institute (PCORI), the PRISM Trial (Pragmatic Randomized Trial of Artificial Intelligence for Screening Mammography) is set to investigate the role of artificial intelligence (AI) in supporting radiologists as they interpret mammograms. The study’s overarching goal is to enhance the accuracy of breast cancer screenings while simultaneously minimizing the incidence of unnecessary callbacks and the associated anxiety that patients often experience.
Unlike previous studies, the PRISM Trial aims to serve thousands of women across multiple states, including California, Florida, Massachusetts, Washington, and Wisconsin. By analyzing hundreds of thousands of mammograms from a network of academic medical centers and breast imaging facilities, this large-scale investigation is designed to generate robust data that can inform clinical practices and policies surrounding breast cancer screening. The AI tool under examination is Transpara, developed by ScreenPoint Medical, and its integration into clinical workflows will be facilitated by the Aidoc aiOS platform, setting the stage for a comprehensive evaluation of its capabilities.
A primary innovation of the PRISM trial is its commitment to patient-centered research. This initiative is not merely a collaboration among researchers and clinicians; it has been developed in close partnership with patient advocates, health system leaders, and policymakers. The input and perspectives from these diverse stakeholders will be invaluable in shaping the design and impact of the study. Patient experience remains paramount, as mammograms will continue to be conducted in accordance with existing clinical protocols, ensuring that there is no disruption to routine screening practices.
Within the framework of the trial, mammograms will be assigned randomly to one of two groups: those interpreted solely by radiologists and those analyzed with AI support. Notably, in every instance, a qualified radiologist will retain the ultimate authority, reading the exam and rendering the final decision regarding diagnosis. This collaborative approach underscores the intention to evaluate how AI may serve as an adjunctive tool that enhances, rather than replaces, human expertise.
Breast cancer remains a prominent health concern, constituting one of the leading causes of cancer-related mortality among women in the United States. Despite the benefits of routine mammography in reducing mortality through early detection, several challenges persist. Among these challenges are the potential for false-positive results, which can lead to unnecessary additional testing, heightened anxiety, and increased healthcare costs. Furthermore, there are instances where significant cancers may be missed altogether, resulting in devastating consequences for patients. The PRISM trial endeavors to assess whether AI can play an integral role in mitigating these challenges, from improving cancer detection rates to reducing the frequency of false positives.
Dr. Joann G. Elmore, Dual Principal Investigator and professor of medicine at UCLA, emphasizes the trailblazing nature of this study: “This is the first large-scale randomized trial of AI in breast cancer screening in the United States.” Her remarks highlight the importance of careful and objective examination to determine whether AI genuinely assists in augmenting radiologist performance or merely increases the number of flagged exams that turn out to be normal. The findings from this study have the potential to significantly influence clinical decision-making and the future integration of AI technology in routine breast cancer screening.
In addition to evaluating the accuracy of cancer detection and recalls, this trial will also utilize focus groups and surveys to delve into the perceptions and trust levels of both patients and radiologists regarding AI-assisted care. Understanding the human experiences associated with AI technology will be crucial in determining how best to implement these advanced systems within healthcare environments.
The collaborative effort in the PRISM trial spans seven leading academic medical centers, showcasing the broad commitment to advancing cancer care across the country. The diverse institutions involved, from UCLA and UC Davis to medical centers in Florida, Massachusetts, and Washington, exemplify a united front in addressing the challenges of breast cancer screening. This multi-institutional approach not only fosters a rich exchange of ideas but also enhances the robustness of the data being collected, ensuring that the findings will be meaningful and applicable across a range of healthcare contexts.
The integration of AI into healthcare raises both opportunities and challenges. While AI holds considerable promise for improving patient outcomes, it also raises essential questions about its real-world effects and implications. Dr. Elmore stresses that rigorous trials like the PRISM initiative are essential for generating trustworthy evidence regarding AI’s utility in clinical practice. The potential of AI to streamline workflows, reduce human error, and enhance diagnostic precision is exhilarating, yet it requires careful validation to ensure that these technologies genuinely provide value without inadvertently compromising patient safety or care quality.
Ultimately, the PRISM trial aims to strike the right balance between human expertise and AI support. The goal is not to supplant the invaluable role of expert radiologists but rather to explore how AI can function as an effective co-pilot in the interpretation of mammograms. Dr. Elmore describes the initiative as an effort to provide expert radiologists with additional resources while maintaining their critical responsibilities in the diagnostic process. This partnership between AI and human judgment is likely to yield new insights into the future of breast cancer screening and may redefine best practices on national and international levels.
Through these groundbreaking efforts, the UCLA and UC Davis-led PRISM Trial aspires to inform future policy decisions and integrate emerging technologies into patient care effectively. The results will likely resonate far beyond the realm of breast cancer screening, paving the way for innovative applications of AI technology in various medical specialties. By prioritizing patient-centered design and maintaining extensive collaboration, this research is poised to make meaningful contributions to the field of oncology, ultimately enhancing care for patients facing the challenges of breast cancer diagnosis and treatment.
The PRISM Trial exemplifies a meticulous approach to intertwining technology with compassionate healthcare delivery, with the primary aim of enhancing patient outcomes while also alleviating the pressures faced by healthcare providers. As the study unfolds over the coming months and years, the insights gained will not only illuminate critical aspects of AI’s role in mammography but could also serve as a model for future integrative studies exploring the intersection of technology and patient care across all domains of medicine.
This is a momentous endeavor, and its findings could resonate broadly, offering hope to many and possibly establishing a new standard for breast cancer screening and care. The collaboration highlights an important juncture in medical history, where technology and the pursuit of improved patient outcomes converge, potentially leading to transformative changes in breast cancer screening practices.
Subject of Research: The role of artificial intelligence in improving mammogram interpretation
Article Title: UCLA and UC Davis Launch PRISM Trial to Enhance Breast Cancer Screening with AI
News Publication Date: October 2023
Web References:
References:
Image Credits:
